References
- Benjamin EJ, Muntner P, Bittencourt MS. Heart disease and stroke statistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56–e528.
- Fox S, Duggan M. Health Online 2013. Pew Internet and American Life Project. 2013. Available from: https://www.pewinternet.org/2013/01/15/health-online-2013/. Accessed July, 2019.
- Patel SA, Winkel M, Ali MK, Narayan KV, Mehta NK. Cardiovascular mortality associated with 5 leading risk factors: national and state preventable fractions estimated from survey data. Ann Intern Med. 2015;163(4):245–253. doi:10.7326/M14-1753
- Oh J-Y, Allison MA, Barrett-Connor E. Different impacts of hypertension and diabetes mellitus on all-cause and cardiovascular mortality in community-dwelling older adults: the Rancho Bernardo Study. J Hypertens. 2017;35(1):55–62. doi:10.1097/HJH.0000000000001145
- Khangura DS, Salam MW, Brietzke SA, Sowers JR. Hypertension in diabetes. In: Endotext [Internet]. MDText. com, Inc.; 2018.
- Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603–615. doi:10.1001/jama.2014.18574
- Deedwania PC. Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy. Cardiol Clin. 2005;23(2):139–152. doi:10.1016/j.ccl.2004.06.006
- Lopez-Jaramillo P, Lopez-Lopez J, Lopez-Lopez C, Rodriguez-Alvarez MI. The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice. Diabetol Metab Syndr. 2014;6(1):31. doi:10.1186/1758-5996-6-31
- Investigators HOPES. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Lancet. 2000;355(9200):253–259.
- Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–153.
- American Diabetes A. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S111–S134.
- Sabaté E, Sabaté E. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization; 2003.
- Vadhariya A, Fleming ML, Johnson ML, et al. Group-based trajectory models to identify sociodemographic and clinical predictors of adherence patterns to statin therapy among older adults. Am Health Drug Benefits. 2019;12(4):202–211.
- van der Wal MH, Jaarsma T. Adherence in heart failure in the elderly: problem and possible solutions. Int J Cardiol. 2008;125(2):203–208. doi:10.1016/j.ijcard.2007.10.011
- Butler RJ, Davis TK, Johnson WG, Gardner HH. Effects of nonadherence with prescription drugs among older adults. Am J Manag Care. 2011;17(2):153–160.
- MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond CA. Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging. 2005;22(3):231–255. doi:10.2165/00002512-200522030-00005
- Hughes CM. Medication non-adherence in the elderly. Drugs Aging. 2004;21(12):793–811. doi:10.2165/00002512-200421120-00004
- Yap AF, Thirumoorthy T, Kwan YH. Systematic review of the barriers affecting medication adherence in older adults. Geriatr Gerontol Int. 2016;16(10):1093–1101. doi:10.1111/ggi.12616
- van Eijken M, Tsang S, Wensing M, de Smet PA, Grol RP. Interventions to improve medication compliance in older patients living in the community. Drugs Aging. 2003;20(3):229–240. doi:10.2165/00002512-200320030-00006
- McLean DL, Simpson SH, McAlister FA, Tsuyuki RT. Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies. Can J Cardiol. 2006;22(10):855–860. doi:10.1016/S0828-282X(06)70304-X
- Kettani F-Z, Dragomir A, Côté R, et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009;40(1):213–220. doi:10.1161/STROKEAHA.108.522193
- Degli Esposti L, Saragoni S, Benemei S, et al. Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients. Clin Econ Outcomes Res. 2011;3:47. doi:10.2147/CEOR.S15619
- Nason GJ, Baker JF, Byrne DP, Noel J, Moore D, Kiely PJ. Scoliosis-specific information on the internet: has the “information highway” led to better information provision? Spine (Phila Pa 1976). 2012;37(21):E1364–1369.
- Academy of Managed Care P, American Pharmacists A. Medicare star ratings: stakeholder proceedings on community pharmacy and managed care partnerships in quality. J Am Pharm Assoc (2003). 2014;54(3):228–240. doi:10.1331/JAPhA.2014.13180
- Nau DP. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence. Springfield, VA: Pharmacy Quality Alliance; 2012.
- Franklin JM, Shrank WH, Pakes J, et al. Group-based trajectory models: a new approach to classifying and predicting long-term medication adherence. Med Care. 2013;51(9):789–796. doi:10.1097/MLR.0b013e3182984c1f
- Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109–138. doi:10.1146/annurev.clinpsy.121208.131413
- Franklin JM, Krumme AA, Shrank WH, Matlin OS, Brennan TA, Choudhry NK. Predicting adherence trajectory using initial patterns of medication filling. Am J Manag Care. 2015;21(9):e537–544.
- Lo-Ciganic WH, Donohue JM, Jones BL, et al. Trajectories of diabetes medication adherence and hospitalization risk: a retrospective cohort study in a large state medicaid program. J Gen Intern Med. 2016;31(9):1052–1060. doi:10.1007/s11606-016-3747-6
- Abughosh SM, Vadhariya A, Johnson ML, et al. Enhancing statin adherence using a motivational interviewing intervention and past adherence trajectories in patients with suboptimal adherence. J Manage Care Spec Pharm. 2019;25(10):1053–1062. doi:10.18553/jmcp.2019.25.10.1053
- Available from: https://wwwcignacom/medicare/medicare-advantage/medicare-advantage-plans-faq. Accessed August 26, 2020.
- Victoria Arrandale MK, MacNab Y, Kennedy SM. How to use SAS® Proc Traj and SAS® Proc Glimmix in Respiratory Epidemiology.
- Odegard PS, Carpinito G, Christensen DB. Medication adherence program: adherence challenges and interventions in type 2 diabetes. J Am Pharm Assoc. 2013;53(3):267–272. doi:10.1331/JAPhA.2013.12065
- Odegard PS, Christensen DB. MAP study: RCT of a medication adherence program for patients with type 2 diabetes. J Am Pharm Assoc (2003). 2012;52(6):753–762. doi:10.1331/JAPhA.2012.11001
- Parikh NM, Morgan RO, Kunik ME, et al. Risk factors for dementia in patients over 65 with diabetes. Int J Geriatr Psychiatry. 2011;26(7):749–757. doi:10.1002/gps.2604
- Johnson ML, Parikh N, Kunik ME, et al. Antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. Alzheimers Dement. 2012;8(5):437–444. doi:10.1016/j.jalz.2011.05.2414
- Dillon P, Stewart D, Smith SM, Gallagher P, Cousins G. Group-based trajectory models: assessing adherence to antihypertensive medication in older adults in a community pharmacy setting. Clin Pharmacol Ther. 2018;103(6):1052–1060. doi:10.1002/cpt.865
- Librero J, Sanfelix-Gimeno G, Peiro S. Medication adherence patterns after hospitalization for coronary heart disease. A population-based study using electronic records and group-based trajectory models. PLoS One. 2016;11(8):e0161381. doi:10.1371/journal.pone.0161381
- Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of glaucoma medication adherence over four years of follow-up. Ophthalmology. 2015;122(10):2010–2021. doi:10.1016/j.ophtha.2015.06.039
- Juarez DT, Williams AE, Chen C, et al. Factors affecting medication adherence trajectories for patients with heart failure. Am J Manag Care. 2015;21(3):e197–205.
- Franklin JM, Krumme AA, Tong AY, et al. Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepidemiol Drug Saf. 2015;24(10):1105–1113. doi:10.1002/pds.3787
- Wang X, Chen H, Essien E, et al. Medication adherence to antihypertensive triple-combination therapy among patients enrolled in a medicare advantage plan. J Manag Care Spec Pharm. 2019;25(6):678–686.
- Medicare Cf, Services M. Medicare 2018 Part C & D Star Ratings Technical Notes. 2017:2017
- Taitel M, Fensterheim L, Kirkham H, Sekula R, Duncan I. Medication days’ supply, adherence, wastage, and cost among chronic patients in Medicaid. Medicare Medicaid Res Rev. 2012;2:3. doi:10.5600/mmrr.002.03.A04
- Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124–1140. doi:10.1161/CIRCRESAHA.118.313220
- Hedna K, Hakkarainen KM, Gyllensten H, et al. Adherence to antihypertensive therapy and elevated blood pressure: should we consider the use of multiple medications? PLoS One. 2015;10(9):e0137451. doi:10.1371/journal.pone.0137451
- Marshall IJ, Wolfe CD, McKevitt C. Lay perspectives on hypertension and drug adherence: systematic review of qualitative research. BMJ. 2012;345:e3953. doi:10.1136/bmj.e3953
- Marcum ZA, Zheng Y, Perera S, et al. Prevalence and correlates of self-reported medication non-adherence among older adults with coronary heart disease, diabetes mellitus, and/or hypertension. Res Social Adm Pharm. 2013;9(6):817–827. doi:10.1016/j.sapharm.2012.12.002
- Asgedom SW, Atey TM, Desse TA. Antihypertensive medication adherence and associated factors among adult hypertensive patients at Jimma University Specialized Hospital, southwest Ethiopia. BMC Res Notes. 2018;11(1):27. doi:10.1186/s13104-018-3139-6
- Saadat Z, Nikdoust F, Aerab-Sheibani H, et al. Adherence to antihypertensives in patients with comorbid condition. Nephrourol Mon. 2015;7(4):e29863. doi:10.5812/numonthly.29863
- Cukor D, Rosenthal DS, Jindal RM, Brown CD, Kimmel PL. Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients. Kidney Int. 2009;75(11):1223–1229. doi:10.1038/ki.2009.51
- Marcum ZA, Gellad WF. Medication adherence to multidrug regimens. Clin Geriatr Med. 2012;28(2):287–300. doi:10.1016/j.cger.2012.01.008
- Lagu T, Weiner MG, Eachus S, Tang SS, Schwartz JS, Turner BJ. Effect of patient comorbidities on filling of antihypertensive prescriptions. Am J Manag Care. 2009;15(1):24–30.
- Kim SJ, Kwon OD, Han EB, et al. Impact of number of medications and age on adherence to antihypertensive medications: a nationwide population-based study. Medicine (Baltimore). 2019;98(49):e17825. doi:10.1097/MD.0000000000017825
- Cho SJ, Kim J. Factors associated with nonadherence to antihypertensive medication. Nurs Health Sci. 2014;16(4):461–467.
- Hashmi SK, Afridi MB, Abbas K, et al. Factors associated with adherence to anti-hypertensive treatment in Pakistan. PLoS One. 2007;2(3):e280. doi:10.1371/journal.pone.0000280
- Marentette MA, Gerth WC, Billings DK, Zarnke KB. Antihypertensive persistence and drug class. Can J Cardiol. 2002;18(6):649–656.
- Shaya FT, Du D, Gbarayor CM, Frech-Tamas F, Lau H, Weir MR. Predictors of compliance with antihypertensive therapy in a high-risk medicaid population. J Natl Med Assoc. 2009;101(1):34–39. doi:10.1016/S0027-9684(15)30808-7
- Lo SH, Chau JP, Woo J, Thompson DR, Choi KC. Adherence to antihypertensive medication in older adults with hypertension. J Cardiovasc Nurs. 2016;31(4):296–303. doi:10.1097/JCN.0000000000000251
- Pan J, Wu L, Wang H, et al. Determinants of hypertension treatment adherence among a Chinese population using the therapeutic adherence scale for hypertensive patients. Medicine (Baltimore). 2019;98(27):e16116. doi:10.1097/MD.0000000000016116
- Pan J, Lei T, Hu B, Li Q. Post-discharge evaluation of medication adherence and knowledge of hypertension among hypertensive stroke patients in northwestern China. Patient Prefer Adherence. 2017;11:1915–1922.
- Yassine M, Al-Hajje A, Awada S, et al. Evaluation of medication adherence in Lebanese hypertensive patients. J Epidemiol Glob Health. 2016;6(3):157–167. doi:10.1016/j.jegh.2015.07.002
- Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497. doi:10.1056/NEJMra050100